Abstract
Positron emission computed tomography (PET) is a functional, noninvasive method for imaging regional metabolic processes that is nowadays most often combined to morphological imaging with computed tomography (CT). Its use is based on the well-founded assumption that metabolic changes occur earlier in tumors than morphologic changes, adding another dimension to imaging. This article will review the established and investigational indications and radiopharmaceuticals for PET/CT imaging for prostate cancer, bladder cancer and testicular cancer, before presenting upcoming applications in radiation therapy.
Keywords: Prostate cancer, bladder cancer, testicular cancer, positron emission tomography, F-18-fluorodeoxyglucose
Current Medicinal Chemistry
Title: Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers
Volume: 17 Issue: 23
Author(s): A. Zouhair, M. Ozsahin, M. Schaffer, S. Albrecht, F. Camus, P. Jichlinski, R.-O. Mirimanoff, A. Bischof Delaloye, J.-Y. Meuwly and J.O. Prior
Affiliation:
Keywords: Prostate cancer, bladder cancer, testicular cancer, positron emission tomography, F-18-fluorodeoxyglucose
Abstract: Positron emission computed tomography (PET) is a functional, noninvasive method for imaging regional metabolic processes that is nowadays most often combined to morphological imaging with computed tomography (CT). Its use is based on the well-founded assumption that metabolic changes occur earlier in tumors than morphologic changes, adding another dimension to imaging. This article will review the established and investigational indications and radiopharmaceuticals for PET/CT imaging for prostate cancer, bladder cancer and testicular cancer, before presenting upcoming applications in radiation therapy.
Export Options
About this article
Cite this article as:
Zouhair A., Ozsahin M., Schaffer M., Albrecht S., Camus F., Jichlinski P., Mirimanoff R.-O., Bischof Delaloye A., Meuwly J.-Y. and Prior J.O., Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers, Current Medicinal Chemistry 2010; 17 (23) . https://dx.doi.org/10.2174/092986710791556014
DOI https://dx.doi.org/10.2174/092986710791556014 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Features in the Regulation of MMP-9 Gene Expression for the Development of Novel Molecular Targets and Therapeutic Strategies
Current Drug Targets - Inflammation & Allergy Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets Bladder Cancer: A Simple Model Becomes Complex
Current Genomics Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Fucose Specific Lectins in Cancer Research and Diagnosis
Drug Design Reviews - Online (Discontinued) Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Prediction of the Ebola Virus Infection Related Human Genes Using Protein-Protein Interaction Network
Combinatorial Chemistry & High Throughput Screening Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism Targeting Cytokines for Morphine Tolerance: A Narrative Review
Current Neuropharmacology Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Synthetic Nanocarriers for Intracellular Protein Delivery
Current Drug Metabolism Circadian Timekeeping in Anticancer Therapeutics: An Emerging Vista of Chronopharmacology Research
Current Drug Metabolism Conjugates of Natural Compounds with Nitroxyl Radicals as a Basis for Creation of Pharmacological Agents of New Generation
Current Medicinal Chemistry miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Overactive Bladder - Current Treatment Modalities
Current Women`s Health Reviews Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Antiproliferative Activity of Olive Oil Phenolics against Human Melan oma Cells
Letters in Drug Design & Discovery